Contemporary Classification of Glucagon-Like Peptide 1 Receptor Agonists (GLP1RAs)

Kalra, Sanjay; Bhattacharya, Saptarshi; Kapoor, Nitin

doi:10.1007/s13300-021-01113-y

Cited by 37 publications

(42 citation statements)

References 71 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…More evidence is needed, however, regarding the impact of oral semaglutide on absorption of alcohol and other drugs and in those with diabetic gastroparesis. This commentary, based on the expert opinion of the authors and suggestions mentioned in other peer-reviewed published papers [ 14 ], shares clinical tips on how to use the drug, in a safe and smart manner, in a wider spectrum of people living with type 2 diabetes. This will ensure rational use of this molecule in a safer and more effective method.…”

Section: Discussionmentioning

confidence: 99%

Oral Semaglutide: Dosage in Special Situations

Kalra

Kapoor

2022

Diabetes Ther

Self Cite

View full text Add to dashboard Cite

Glucagon-like peptide 1 receptor agonists (GLP1RAs) have recently gained momentum after the introduction of semaglutide, the first oral molecule in their class. In a recent article in this journal by Evans et al., a succinct overview of the utility of semaglutide is highlighted in the context of virtual diabetes care. To take this discussion further, this commentary describes the value and positioning of oral semaglutide in common clinical situations. Its insights assist in pragmatic placement of this drug in clinical practice. Special emphasis is laid on the use of oral semaglutide in persons already on injectable GLP-1RA formulations, those experiencing sudden changes in life style pattern due to religious, social, or professional commitments, individuals seeking help for urgent glycemic control, and those who face sudden change in their concomitant medications or comorbidities.

show abstract

Section: Discussionmentioning

confidence: 99%

Oral Semaglutide: Dosage in Special Situations

Kalra

Kapoor

2022

Diabetes Ther

Self Cite

View full text Add to dashboard Cite

show abstract

“…[ 32 ] Emerging data from randomized clinical trials using GLP-1 analogues seem to be effective in reducing weight and improving glycemic control in the subset of patients from the South East Asian region. [ 33 ]…”

Section: P Revalence Of O Besity In ...mentioning

confidence: 99%

ESI Clinical Practice Guidelines for the Evaluation and Management of Obesity In India

Madhu

Kapoor

Das

et al. 2022

Indian Journal of Endocrinology and Metabolism

View full text Add to dashboard Cite

“…Hence, several modifications of this peptide have been attempted with great success in order to establish clinically useful drugs. Two types of GLP1RA are used in the treatment of diabetes and its complications: exendin-based derivatives and human GLP1 analogues [ 83 ]. Exenatide, a synthetic analogue of exendin-4, the natural GLP1RA, is the first peptide approved for the treatment of diabetes [ 84 , 85 ].…”

Section: Glp1ra As Antioxidative and Anti-inflammatory Agents In Dkd And Other Models Of Kidney Injurymentioning

confidence: 99%

Inflammation and Oxidative Stress in Diabetic Kidney Disease: The Targets for SGLT2 Inhibitors and GLP-1 Receptor Agonists

Winiarska

Knysak

Nabrdalik

et al. 2021

IJMS

111

View full text Add to dashboard Cite

The incidence of type 2 diabetes (T2D) has been increasing worldwide, and diabetic kidney disease (DKD) remains one of the leading long-term complications of T2D. Several lines of evidence indicate that glucose-lowering agents prevent the onset and progression of DKD in its early stages but are of limited efficacy in later stages of DKD. However, sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor (GLP-1R) antagonists were shown to exert nephroprotective effects in patients with established DKD, i.e., those who had a reduced glomerular filtration rate. These effects cannot be solely attributed to the improved metabolic control of diabetes. In our review, we attempted to discuss the interactions of both groups of agents with inflammation and oxidative stress—the key pathways contributing to organ damage in the course of diabetes. SGLT2i and GLP-1R antagonists attenuate inflammation and oxidative stress in experimental in vitro and in vivo models of DKD in several ways. In addition, we have described experiments showing the same protective mechanisms as found in DKD in non-diabetic kidney injury models as well as in some tissues and organs other than the kidney. The interaction between both drug groups, inflammation and oxidative stress appears to have a universal mechanism of organ protection in diabetes and other diseases.

show abstract

Contemporary Classification of Glucagon-Like Peptide 1 Receptor Agonists (GLP1RAs)

Cited by 37 publications

References 71 publications

Oral Semaglutide: Dosage in Special Situations

Oral Semaglutide: Dosage in Special Situations

ESI Clinical Practice Guidelines for the Evaluation and Management of Obesity In India

Inflammation and Oxidative Stress in Diabetic Kidney Disease: The Targets for SGLT2 Inhibitors and GLP-1 Receptor Agonists

Contact Info

Product

Resources

About